Pierce, William F.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 255

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 180

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 105

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 99